Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Deals M & A

QUOTED. 10 January 2020. Francis deSouza.

  • News

Executive Summary

Illumina Inc. has agreed to pay $98m to terminate its merger agreement with Pacific Biosciences of California Inc. following opposition from antitrust regulators in the US and UK. See what Illumina CEO Francis deSouza said about it here.

“We believe this proposed combination would have broadened access to Pacific Biosciences' sequencing technology, significantly expanded and accelerated innovation, and ultimately increased the clinical utility and impact of sequencing.” – Francis deSouza, CEO, Illumina Inc.

Click here for a free trial of Medtech Insight

 
Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Deals M & A
Latest Headlines

MHRA Sets Out Summer Schedule Of Medtech Regulatory Milestones

Apple Watch Feature Qualified As FDA Device Development Tool

Expert Proposes AI Device Reimbursement Model ‘Like Netflix’

Robotic-Assisted Treatment For Enlarged Prostate Shows Promising Results

See All
UsernamePublicRestriction

Register

MT126089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By